Prelude Therapeutics (PRLD) Set to Post Quarterly Earnings on Wednesday

Prelude Therapeutics (NASDAQ:PRLD) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of $0.0040 per share and revenue of $29.00 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:00 AM ET.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. The firm had revenue of $5.70 million during the quarter, compared to analysts’ expectations of $5.70 million. On average, analysts expect Prelude Therapeutics to post ($0.57) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

Prelude Therapeutics Stock Down 1.6%

Shares of Prelude Therapeutics stock opened at $3.78 on Wednesday. The firm has a market cap of $301.64 million, a price-to-earnings ratio of -5.18 and a beta of 1.22. Prelude Therapeutics has a 52-week low of $1.17 and a 52-week high of $6.83. The company’s 50-day simple moving average is $4.34 and its 200-day simple moving average is $4.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PRLD shares. JPMorgan Chase & Co. initiated coverage on Prelude Therapeutics in a report on Thursday, September 17th. They issued an “overweight” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Prelude Therapeutics in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Tuesday, October 27th. Citigroup reissued a “market outperform” rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. Finally, Wall Street Zen downgraded Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Prelude Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights into cancer biology to design small-molecule therapies intended to target vulnerabilities in tumor cells while potentially improving selectivity over healthy tissue.

Prelude’s research and development programs have included targeted therapies aimed at cancer-related proteins and signaling pathways, including cyclin-dependent kinase 9 (CDK9) and other regulators of tumor growth and survival.